Mei-Yin Polley to Breast Neoplasms
This is a "connection" page, showing publications Mei-Yin Polley has written about Breast Neoplasms.
Connection Strength
1.456
-
On the Quest of Risk Stratification in HER2-Positive Breast Cancer. J Natl Cancer Inst. 2022 03 08; 114(3):345-346.
Score: 0.320
-
A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy. Breast Cancer Res Treat. 2021 Aug; 189(1):15-23.
Score: 0.305
-
A clinical calculator to predict disease outcomes in women with triple-negative breast cancer. Breast Cancer Res Treat. 2021 Feb; 185(3):557-566.
Score: 0.295
-
An international study to increase concordance in Ki67 scoring. Mod Pathol. 2015 Jun; 28(6):778-86.
Score: 0.196
-
CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. J Clin Oncol. 2022 04 20; 40(12):1323-1334.
Score: 0.079
-
Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2021 07 01; 113(7):808-819.
Score: 0.076
-
Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. J Clin Oncol. 2020 12 10; 38(35):4184-4193.
Score: 0.073
-
Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. J Clin Oncol. 2019 09 10; 37(26):2338-2348.
Score: 0.067
-
An international Ki67 reproducibility study. J Natl Cancer Inst. 2013 Dec 18; 105(24):1897-906.
Score: 0.045